MedPath

GSK's GSK5764227 Receives FDA Breakthrough Therapy Designation for Osteosarcoma

• GSK5764227, a B7-H3-targeted antibody-drug conjugate, has been granted Breakthrough Therapy Designation by the FDA for osteosarcoma treatment. • The designation aims to accelerate the development and review of GSK5764227 for relapsed or refractory osteosarcoma in adults. • This is the third regulatory designation for GSK5764227, highlighting its potential in treating serious conditions with limited therapeutic options. • The FDA's decision is based on preliminary clinical evidence suggesting substantial improvement over existing therapies for bone cancer.

GSK's GSK5764227, an antibody-drug conjugate (ADC) targeting B7-H3, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory osteosarcoma who have progressed on at least two prior lines of therapy. This designation aims to expedite the development and review of GSK5764227, recognizing its potential to offer a substantial improvement over existing therapies for this serious condition.
This regulatory milestone marks the third designation for GSK5764227, following the European Medicines Agency's PRIME designation and the FDA's Breakthrough Therapy Designation for relapsed or refractory extensive-stage small-cell lung cancer, granted in August and December 2024, respectively. These designations underscore the drug's promise in addressing unmet needs across different cancer types.

Significance of Breakthrough Therapy Designation

The FDA's Breakthrough Therapy Designation is reserved for drugs intended to treat a serious condition, where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies. This designation provides GSK with increased access to the FDA during the development process, potentially accelerating the drug's path to market.

Osteosarcoma and Unmet Needs

Osteosarcoma is a rare primary bone cancer that predominantly affects children and young adults. Relapsed or refractory osteosarcoma, where the cancer returns after treatment or does not respond to initial therapy, presents a significant challenge. Current treatment options are limited, highlighting the urgent need for novel therapies like GSK5764227.

GSK5764227: A B7-H3 Targeted ADC

GSK5764227 is an antibody-drug conjugate (ADC) that targets B7-H3, a protein expressed in various cancers, including osteosarcoma. By targeting B7-H3, GSK5764227 aims to deliver a cytotoxic payload directly to cancer cells, minimizing damage to healthy tissues. The ongoing clinical trials are evaluating the safety and efficacy of GSK5764227 in patients with relapsed or refractory osteosarcoma.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

GSK's Bepirovirsen Receives FDA Fast Track for Chronic Hepatitis B Treatment

The FDA has granted fast-track designation to GSK's bepirovirsen, an antisense drug, for chronic hepatitis B (CHB) treatment, expediting its review process.
Bepirovirsen is the only single agent in phase 3 trials showing potential for a functional cure when combined with standard nucleoside/nucleotide analogue (NA) therapies.

GSK's Cancer Portfolio Gains Momentum with Regulatory Successes for Dostarlimab and GSK'227

Dostarlimab plus chemotherapy receives positive CHMP opinion for expanded approval in primary advanced or recurrent endometrial cancer, including mismatch repair proficient/microsatellite stable tumors.
Dostarlimab also gains FDA Breakthrough Therapy Designation for locally advanced mismatch repair deficient/microsatellite instability-high rectal cancer, showing 100% disease-free response in treated patients.

GSK's GSK'227 Receives FDA Breakthrough Therapy Designation for Relapsed Osteosarcoma

The FDA granted Breakthrough Therapy Designation to GSK'227 for relapsed or refractory osteosarcoma after two prior lines of therapy.
The designation aims to expedite the development of GSK'227, a B7-H3-targeted antibody-drug conjugate, for this rare bone cancer.

uniQure Receives FDA Nod for Accelerated Approval Pathway for Huntington's Disease Gene Therapy

uniQure secured FDA agreement to pursue accelerated approval for its Huntington's disease gene therapy, potentially expediting treatment availability.
The FDA's decision reflects a more flexible approach to genetic medicines for severe rare diseases under Peter Marks.

FDA to Review Belantamab Mafodotin and Linvoseltamab Combinations for Multiple Myeloma

The FDA has accepted a BLA for belantamab mafodotin combinations with bortezomib plus dexamethasone and pomalidomide plus dexamethasone for multiple myeloma treatment.
Regeneron's linvoseltamab BLA resubmission has been accepted by the FDA, with a decision expected by July 10, 2025, for relapsed/refractory multiple myeloma.

GSK's Blenrep Receives Breakthrough Therapy Designation in China and Japan Review for Multiple Myeloma

GSK's Blenrep (belantamab mafodotin) gains Breakthrough Therapy Designation in China for relapsed or refractory multiple myeloma when combined with bortezomib plus dexamethasone.
The designation is based on Phase III DREAMM-7 trial results, demonstrating statistically significant improvements in progression-free survival compared to daratumumab plus BorDex.

GSK's GSK5764227 Receives FDA Breakthrough Therapy Designation for Extensive-Stage Small Cell Lung Cancer

The FDA granted Breakthrough Therapy Designation to GSK5764227 for extensive-stage small cell lung cancer (ES-SCLC) post-platinum chemotherapy.
The designation is based on Phase 1 ARTEMIS-001 trial data, showing promising efficacy and manageable toxicity in pretreated solid tumors.

FDA Grants Orphan Drug Designation to Mabwell's 7MW3711 for Small Cell Lung Cancer

The FDA has granted Orphan Drug Designation to 7MW3711, a novel B7-H3-targeting antibody-drug conjugate (ADC), for the treatment of small cell lung cancer (SCLC).
7MW3711, developed using Mabwell's IDDC™ platform, has demonstrated superior tumor-killing effects compared to other ADCs in preclinical models, showing a promising safety profile.

FDA Grants Breakthrough Therapy Designation for GSK's Osteosarcoma Treatment

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for GSK's GSK'227, a B7-H3-targeted antibody-drug conjugate, for treating relapsed or refractory osteosarcoma in adults. This decision is based on promising data from the ARTEMIS-002 study, highlighting the drug's potential in addressing a significant unmet medical need.

GSK's BCMA-Targeting ADC, GSK2857916, Receives FDA Breakthrough Therapy Designation for Multiple Myeloma

GSK2857916, an investigational BCMA-targeting antibody-drug conjugate, has been granted Breakthrough Therapy Designation by the FDA for relapsed/refractory multiple myeloma.
The designation is for patients who have failed at least three prior lines of therapy, including an anti-CD38 antibody, and are refractory to proteasome inhibitors and immunomodulatory agents.

Reference News

[1]
GSK bone cancer treatment granted FDA breakthrough ...
borsaitaliana.it · Nov 7, 2016

GSK's B7-H3-targeted antibody-drug conjugate, GSK'227, received FDA Breakthrough Therapy Designation for treating relaps...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy